Indo.Dh
INDO.DH operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
Business. Indonesia Energy Corp Ltd (INDO.K) is an oil and gas exploration and production company operating within the fossil fuels sector. The firm is headquartered in Indonesia and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Indonesia Energy Corp Ltd (INDO.K) is an oil and gas exploration and production company operating within the fossil fuels sector. The firm is headquartered in Indonesia and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
INDO.DH's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and no going-concern language is present in the source documents. This absence of data prevents a full assessment of the company's liquidity position.
Profitability and return metrics for INDO.DH cannot be evaluated due to the lack of financial data in the valuation snapshot. Without access to key performance indicators such as return on invested capital (ROIC) or operating margins, it is not possible to compare the company's performance against industry benchmarks or cohort medians.
INDO.DH's segment and geographic exposure remain undisclosed in the available data. There is no information provided on revenue concentration by product line or geographic region, which limits the ability to assess the company's diversification and exposure to regional economic conditions.
The growth trajectory of INDO.DH is indeterminate due to the absence of outlook data and revenue history. Without numeric deltas or forward-looking guidance, it is not possible to assess the company's expected performance in the current or next fiscal year.
Risk factors for INDO.DH include the inability to assess liquidity risk, as no balance-sheet inputs are available and no going-concern language is present in the source documents. There is no indication of dilution potential, as the number of basic and diluted shares outstanding is identical, and no adjustments have been applied to the valuation metrics.
Recent events and filings for INDO.DH are not disclosed in the available data. There are no transcripts or filings provided that would indicate recent strategic moves, earnings reports, or other material events affecting the company.
- INDO.DH's business model centers on pharmaceutical development and commercialization, but detailed financials are not available.
- The company's classification is well-defined within the healthcare sector, with a high confidence level.
- There is insufficient data to assess INDO.DH's liquidity, profitability, or growth trajectory.
- No dilution risk is currently indicated, but the lack of financial data limits the ability to evaluate this further.
- Recent events and strategic developments for INDO.DH are not disclosed in the available data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- INDO.DH Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 36.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 8.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -24.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 22.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -76.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 19.6%Derived (calculated)
- Net margin (FY 2025-12-31): -253.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -25.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -22.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 5.13xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.16xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 36.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -16.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2022-12-31): 2,553.9%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Revenue (annual): USD 2.01MSEC XBRL filing
- Current assets (annual): USD 7.5MSEC XBRL filing
- Total liabilities (annual): USD 3.1MSEC XBRL filing
- Pre-tax income (annual): USD -5.1MSEC XBRL filing
- Current liabilities (annual): USD 1.46MSEC XBRL filing
- Total assets (annual): USD 22.76MSEC XBRL filing
- Operating cash flow (annual): USD -5.43MSEC XBRL filing